BZLF1 transcript variants in Epstein-Barr virus-positive epithelial cell lines.

Area of Science:

• Virology
• Molecular Biology
• Cancer Research

Background:

• Epstein-Barr virus (EBV) infects over 90% of the population, linked to lymphomas and carcinomas.
• BZLF1 and BRLF1 immediate-early genes regulate EBV lytic replication.
• BZLF1 splicing in B lymphocytes yields fully spliced or zDelta variants; epithelial cell splicing is uncharacterized.

Purpose of the Study:

• To characterize alternative splicing of the BZLF1 gene in EBV-positive epithelial cells.
• To investigate the effect of mTOR pathway inhibition on BZLF1 transcript variants.

Main Methods:

• Analysis of BZLF1 transcripts in EBV-positive epithelial cell lines (D98/HR1, AGS-BDneo, AGS-BX1).
• Comparison of BZLF1 splicing patterns in epithelial cells versus B-cell lines (B95-8, IM-9, Raji, Daudi).
• Assessment of rapamycin's impact on specific BZLF1 transcript variant production.

Main Results:

• Three distinct BZLF1 transcripts were identified in epithelial cells: fully spliced, unspliced, and exon 1-3 spliced.
• B-cell lines exclusively showed the fully spliced BZLF1 transcript.
• Rapamycin treatment differentially altered BZLF1 transcript variant production in a cell-type and variant-specific manner.

Conclusions:

• EBV exhibits distinct BZLF1 alternative splicing patterns in epithelial cells compared to B-cells.
• mTOR pathway inhibition influences EBV BZLF1 transcript variant expression.
• These BZLF1 transcript variants may modulate EBV replication in epithelial cells.